Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026
- Dr. GPCR News
- 9 hours ago
- 3 min read
If you’ve felt the pace of GPCR research accelerating—and the signal getting harder to separate from the noise—you’re not alone.
This week marks the start of a new era for the Dr. GPCR Ecosystem: sharper programming, deeper expertise, and renewed momentum across everything we publish and build.
After a brief pause over the holidays and last month, we’re back in full force—designed to help you make better scientific and strategic decisions, faster.
Latest breakthroughs : Lilly confirms Q4 2025 results call; Novo Nordisk explores monthly GLP-1 acquisition; 2025 Fellows announced, including Dr. Terry Kenakin; GIP receptor agonist patent WO2025264700.
🔍 This Week in Dr.GPCR Premium: Sneak Peek
Upcoming events: 5th GPCRs Targeted Drug Discovery Summit, Boston.
Career opportunities: In vitro Pharmacology Research Assistant—Geneva.
Must-read publications: GPCRs in neurological disorders; OSTα-OSTβ structure; GPCR–G protein–β-arrestin megacomplex.
A New Era for the Dr. GPCR Ecosystem
The Ecosystem has been evolving over the years—expanding into an integrated platform for learning, insight, and connection.
We have shifted to continuous, coordinated programming across Weekly News, Terry’s Corner, the Podcast, and now the Dr. GPCR University.
This isn’t about more content. It’s about better alignment: helping scientists, drug hunters, and decision-makers stay grounded in fundamentals while keeping pace with modern GPCR research and drug discovery.
What this new phase delivers:
Continuity across formats — concepts reinforced through articles, lectures, and conversations.
Clearer signals — curated insights that reduce noise without oversimplifying complexity.
Community presence — from conferences to collaborative initiatives built in public.
Terry’s Corner—Basic Pharmacokinetics
Pharmacokinetics isn’t a late-stage checkbox—it’s a decision framework that shapes every viable drug discovery program. In this lesson, Dr. Terry Kenakin reframes PK as a predictive, manageable discipline, not an unavoidable bottleneck.
Rather than chasing potency alone, this session equips drug hunters with system-level thinking: how ADME properties govern exposure, efficacy, and safety long before clinical translation.
Why this matters now:
PK defines translatability — activity without exposure is not pharmacology.
Optimization is modular — activity, ADME, and safety can be tuned independently.
Early assays prevent late failure — modern in vitro tools dramatically reduce attrition.
Want to learn more? Here's how:
Dr. GPCR Podcast—GPCR Assay Strategy, Bias, and Translational Drug Discovery
In this episode of the Dr. GPCR podcast , Dr. Martin Marro shares hard-earned lessons from the interface of assays, bias, and translation.
The conversation moves beyond theory into real-world tradeoffs: fluorescence-based assays, internalization readouts, antibody discovery, and the persistent gap between in vitro promise and in vivo reality.
Listeners will gain perspective on:
Assay choice as strategy, not convenience.
Bias agonism pitfalls that emerge during translation.
Leadership decisions that keep multidisciplinary teams aligned.
Why Dr. GPCR Premium Membership Gives You an Edge
Dr. GPCR Premium is designed for scientists and teams who can’t afford to chase every headline—or miss the ones that matter. Premium delivers curated, noise-free intelligence every week: expert lectures, classified industry updates, upcoming events, career opportunities, and insider commentary.
Instead of fragmented inputs, members get a coherent view of the GPCR landscape—connecting fundamentals to application, and research signals to real-world decisions. Your membership also supports open educational resources for the global GPCR community, ensuring depth, rigor, and accessibility remain central to the field.
FAQ
🔹 What’s included? The complete Weekly News digest, curated jobs and events, classified GPCR publications, on-demand expert frameworks, GPCR University access, and member-only discounts.
🔹 Who is it for? GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need fast, relevant intelligence to stay ahead.
🔹 Why now? GPCR innovation is accelerating. Those acting on the right signals today will shape tomorrow’s breakthroughs—and avoid delays others won’t see coming.
Already a Premium Member? 👉 Access this week’s full Premium Edition here ➤
From the Community
“Great initiative—clear guidance on career paths, choosing research topics, switching fields, and learning from both failures and successes.”
This is just the beginning.
With new courses, expanded programming, upcoming partnerships, and deeper community engagement ahead, the Dr. GPCR Ecosystem is entering its most ambitious phase yet.
If you want to stay informed, connected, and prepared for what’s next in GPCR science—now is the moment to step in.
Yamina and the Dr. GPCR Team
Comments